Drug intelligence / Profile preview

prostarine

Development stage: Discontinued
Lead developer: GTx
Modality: Small Molecules
Administration: Oral

Overview

Prostarine is a selective androgen receptor modulator (SARM) that was developed by GTx, Inc. for the treatment of benign prostatic hyperplasia (BPH). Originally discovered by researchers at the University of Tennessee, Prostarine was designed to selectively bind to the androgen receptor, aiming to reduce prostate volume while avoiding the side effects typically associated with non-selective androgen therapies. The compound was part of GTx's early pipeline in the mid-2000s but did not progress into late-stage clinical development as the company shifted its focus toward other SARM candidates such as enobosarm.

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on prostarine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on prostarine.

Explore the full profile